J. Shi

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy

O. Tayber, B. Modrell, James I. Kim, 2022, Cancer Immunology, Immunotherapy.

Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines

T. Vos, A. Chakravarty, B. Amidon, 2014, PloS one.

MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma

Ray Liu, M. Duffey, T. Vos, 2012, Molecular Cancer Therapeutics.

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

S. Tirrell, J. Newcomb, T. Soucy, 2018, Nature Medicine.

TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies

T. Traore, V. Kolev, M. Okaniwa, 2022, Cancer research communications.

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

R. Davis, S. Tirrell, A. Berger, 2019, Blood.

Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug–drug interaction profiles

C. Li, C. Xia, M. Liao, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Article Title: TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies Short Title: TNT003 inhibits CA driven complement activation Designation: Immunobiology

G. Parry, N. Stagliano, S. Panicker, 2014 .